BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 29247781)

  • 1. Killer Cell Immunoglobulin-Like Receptor-Ligand Mismatch in Donor versus Recipient Direction Provides Better Graft-versus-Tumor Effect in Patients with Hematologic Malignancies Undergoing Allogeneic T Cell-Replete Haploidentical Transplantation Followed by Post-Transplant Cyclophosphamide.
    Wanquet A; Bramanti S; Harbi S; Fürst S; Legrand F; Faucher C; Granata A; Calmels B; Lemarie C; Picard C; Chabannon C; Weiller PJ; Castagna L; Blaise D; Devillier R
    Biol Blood Marrow Transplant; 2018 Mar; 24(3):549-554. PubMed ID: 29247781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide.
    Shimoni A; Labopin M; Lorentino F; Van Lint MT; Koc Y; Gülbas Z; Tischer J; Bruno B; Blaise D; Pioltelli P; Afanasyev B; Ciceri F; Mohty M; Nagler A
    Leukemia; 2019 Jan; 33(1):230-239. PubMed ID: 29907809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donor KIR2DS1-Mediated Decreased Relapse and Improved Survival Depending on Remission Status at HLA-Haploidentical Transplantation with Post-Transplantation Cyclophosphamide.
    Ido K; Koh H; Hirose A; Okamura H; Koh S; Nanno S; Nishimoto M; Nakamae M; Nakashima Y; Nakane T; Hino M; Nakamae H
    Biol Blood Marrow Transplant; 2020 Apr; 26(4):723-733. PubMed ID: 31899360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donor Selection Based on Killer Cell Immunoglobulin-Like Receptor (KIR) Genotype May Improve Outcome After T-Cell-Replete Haploidentical Transplantation.
    Torío A; Pascual MJ; Vidales I; Ortiz M; Caballero A; Heiniger AI
    Transplant Proc; 2018 Mar; 50(2):679-682. PubMed ID: 29579887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory killer cell immunoglobulin-like receptor (iKIR) mismatches improve survival after T-cell-repleted haploidentical transplantation.
    Bastos-Oreiro M; Anguita J; Martínez-Laperche C; Fernández L; Buces E; Navarro A; Pascual C; Pérez-Corral A; Balsalobre P; Muñoz C; Kwon M; Serrano D; Perez-Martinez A; Buño I; Gayoso J; Díez-Martín JL
    Eur J Haematol; 2016 May; 96(5):483-91. PubMed ID: 26133015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation.
    Symons HJ; Leffell MS; Rossiter ND; Zahurak M; Jones RJ; Fuchs EJ
    Biol Blood Marrow Transplant; 2010 Apr; 16(4):533-42. PubMed ID: 19961944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donor Killer Immunoglobulin-Like Receptor Haplotype B/x Induces Severe Acute Graft-versus-Host Disease in the Presence of Human Leukocyte Antigen Mismatch in T Cell-Replete Hematopoietic Cell Transplantation.
    Hosokai R; Masuko M; Shibasaki Y; Saitoh A; Furukawa T; Imai C
    Biol Blood Marrow Transplant; 2017 Apr; 23(4):606-611. PubMed ID: 28042021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recipient-donor KIR ligand matching prevents CMV reactivation post-haploidentical T cell-replete transplantation.
    Zhao XY; Luo XY; Yu XX; Zhao XS; Han TT; Chang YJ; Huo MR; Xu LP; Zhang XH; Liu KY; Li D; Jiang ZF; Huang XJ
    Br J Haematol; 2017 Jun; 177(5):766-781. PubMed ID: 28466469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?
    Chang YJ; Luznik L; Fuchs EJ; Huang XJ
    J Hematol Oncol; 2016 Apr; 9():35. PubMed ID: 27071449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
    Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
    Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Hodgkin Lymphoma Relapsed after Autologous Transplantation: Reduced Incidence of Relapse and of Chronic Graft-versus-Host Disease Compared with HLA-Identical Related Donors.
    Mariotti J; Devillier R; Bramanti S; Sarina B; Furst S; Granata A; Faucher C; Harbi S; Morabito L; Chabannon C; Carlo-Stella C; Bouabdallah R; Santoro A; Blaise D; Castagna L
    Biol Blood Marrow Transplant; 2018 Mar; 24(3):627-632. PubMed ID: 29197681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective analysis to evaluate if KIR B haplotype donors associate with a reduced risk of relapse in patients with haematological malignancies following haploidentical transplantation at the Blood and Bone Marrow Transplant Unit at Hammersmith Hospital ICHNHST.
    Byrnes CP; Hastings A; Lacej I; Palanicawandar R; Olavarria E; Anand A
    HLA; 2024 Jan; 103(1):e15214. PubMed ID: 37712429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haploidentical T Cell-Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen-Matched Related or Unrelated Donor.
    Blaise D; Fürst S; Crocchiolo R; El-Cheikh J; Granata A; Harbi S; Bouabdallah R; Devillier R; Bramanti S; Lemarie C; Picard C; Chabannon C; Weiller PJ; Faucher C; Mohty B; Vey N; Castagna L
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):119-24. PubMed ID: 26341397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Negative Impact of Unidirectional Host-versus-Graft Killer Cell Immunoglobulin-like Receptor Ligand Mismatch on Transplantation Outcomes after Unmanipulated Haploidentical Peripheral Blood Stem Cell Transplantation for Acute Myeloid Leukemia.
    Yahng SA; Jeon YW; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Kim HJ
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):316-323. PubMed ID: 26415557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selecting the Best Donor for Haploidentical Transplant: Impact of HLA, Killer Cell Immunoglobulin-Like Receptor Genotyping, and Other Clinical Variables.
    Solomon SR; Aubrey MT; Zhang X; Piluso A; Freed BM; Brown S; Jackson KC; Morris LE; Holland HK; Solh MM; Bashey A
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):789-798. PubMed ID: 29355721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Donor Activating KIR-HLA Ligand-Mediated NK Cell Education Status in Control of Malignancy in Hematopoietic Cell Transplant Recipients.
    Nowak J; Kościńska K; Mika-Witkowska R; Rogatko-Koroś M; Mizia S; Jaskuła E; Polak M; Mordak-Domagała M; Lange J; Gronkowska A; Jędrzejczak WW; Kyrcz-Krzemień S; Markiewicz M; Dzierżak-Mietła M; Tomaszewska A; Nasiłowska-Adamska B; Szczepiński A; Hałaburda K; Hellmann A; Czyż A; Gil L; Komarnicki M; Wachowiak J; Barańska M; Kowalczyk J; Drabko K; Goździk J; Wysoczańska B; Bogunia-Kubik K; Graczyk-Pol E; Witkowska A; Marosz-Rudnicka A; Nestorowicz K; Dziopa J; Szlendak U; Warzocha K; Lange A;
    Biol Blood Marrow Transplant; 2015 May; 21(5):829-39. PubMed ID: 25617806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural Killer Cell Alloreactivity Predicted By Killer Cell Immunoglobulin-Like Receptor Ligand Mismatch Does Not Impact Engraftment in Umbilical Cord Blood and Haploidentical Stem Cell Transplantation.
    Otegbeye F; Vina MAF; Wang T; Bolon YT; Lazaryan A; Beitinjaneh A; Bhatt VR; Castillo P; Marsh SGE; Hildebrandt GC; Assal A; Brown VI; Hsu J; Spellman S; de Lima M; Lee SJ
    Transplant Cell Ther; 2022 Aug; 28(8):483.e1-483.e7. PubMed ID: 35643351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide/Bendamustine in Pediatric and Young Adult Patients with Hematologic Malignancies.
    Katsanis E; Sapp LN; Varner N; Koza S; Stea B; Zeng Y
    Biol Blood Marrow Transplant; 2018 Oct; 24(10):2034-2039. PubMed ID: 29908231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy.
    Hsu KC; Gooley T; Malkki M; Pinto-Agnello C; Dupont B; Bignon JD; Bornhäuser M; Christiansen F; Gratwohl A; Morishima Y; Oudshoorn M; Ringden O; van Rood JJ; Petersdorf E;
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):828-36. PubMed ID: 16864053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incorporation of high-dose
    Lee JW; Kang ES; Sung KW; Yi E; Lee SH; Yoo KH; Koo HH
    Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 28012219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.